Chugai Pharmaceutical, a subsidiary of Roche, has submitted an application for regulatory approval of Vamikibart in Japan. The drug is intended for the treatment of uveitic macular edema (UME) associated with non-infectious uveitis, a condition that may result in vision loss if left untreated.
If approved, Vamikibart would become the first anti-IL-6 antibody therapy available in Japan for this indication, according to a statement from Roche. The company noted that Vamikibart received Orphan Drug Status in Japan at the end of June, a designation granted to therapies targeting rare diseases or conditions with limited treatment options.
Chugai’s submission follows clinical development efforts to address UME, a complication of non-infectious uveitis that can cause significant visual impairment. The application marks a step forward in expanding treatment options for patients with this condition in Japan.
